prof. dr. ir. Kathleen Claes
work address
De Pintelaan 185, ingang 34 (MRB)
9000 Gent
9000 Gent
ORCID iD
0000-0003-0841-7372
1 – 10 of 122
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2017
- Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores
- Evaluation of polygenic risk scores for breast and ovarian cancer risk prediction in BRCA1 and BRCA2 mutation carriers
- BRCA2 hypomorphic missense variants confer moderate risks of breast cancer
- Second hit landscape in BRCA-associated breast cancer
- Analysis of chromosomal radiosensitivity of healthy BRCA2 mutation carriers and non-carriers in BRCA families with the G2 micronucleus assay
- PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS
- Incorporating PARP-inhibitors into clinical routine : a tailored treatment strategy to tackle ovarian cancer
- 2016
- Studying the functionality of the homologous repair pathway in zebrafish embryos : heading for an in vivo functional test to evaluate the pathogenicity of BRCA2 variants
- Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 women
- Development of a blood test for selection of lung cancer patients who could benefit from immunotherapy.